Compagnie Lombard Odier SCmA’s BeOne Medicines Ltd ONC Stock Holding History

Compagnie Lombard Odier SCmA’s Portfolio ONC Stock Details ONC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-407	Closed	-$83.2K	–	491
2024 Q3	$91.4K	Hold	407	–	–	﹤0.01%	300
2024 Q2	$58.1K	Hold	407	–	–	﹤0.01%	323
2024 Q1	$63.7K	Hold	407	–	–	﹤0.01%	335
2023 Q4	$73.4K	Hold	407	–	–	﹤0.01%	375
2023 Q3	$73.2K	Hold	407	–	–	﹤0.01%	390
2023 Q2	$72.6K	Hold	407	–	–	﹤0.01%	381
2023 Q1	$87.7K	Hold	407	–	–	﹤0.01%	390
2022 Q4	$90K	Hold	407	–	–	﹤0.01%	403
2022 Q3	$55K	Buy	+407	New	+$69.9K	﹤0.01%	454

Other funds holding ONC

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Compagnie Lombard Odier SCmA's ONC Position: Q4 2024 in Review

Compagnie Lombard Odier SCmA sold out of BeOne Medicines Ltd (ONC) in Q4 2024, closing a stake of 407 shares — an estimated $83.2K sold.

Compagnie Lombard Odier SCmA first reported a position in ONC in Q3 2022 and held it in 9 quarters. The position peaked at $91.4K in Q3 2024. 229 funds tracked by Wall St. Rank hold ONC as of Q4 2024.

Compagnie Lombard Odier SCmA reported no remaining BeOne Medicines Ltd position as of Q4 2024 after selling out during the quarter.
Compagnie Lombard Odier SCmA sold 407 BeOne Medicines Ltd shares in Q4 2024, an estimated $83.2K.
Compagnie Lombard Odier SCmA first reported a position in BeOne Medicines Ltd in Q3 2022 and held it in 9 quarters.
Compagnie Lombard Odier SCmA's BeOne Medicines Ltd position peaked at $91.4K in Q3 2024.
229 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q4 2024.

Based on Compagnie Lombard Odier SCmA's 13F filing for Q4 2024, filed 30 Jan 2025.